Toshio Kitamura

List of Publications by Year
in descending order

148 papers	8,553 citations	53660 45 h-index	46693 89 g-index
156 all docs	156 docs citations	156 times ranked	11886 citing authors

#	Article	IF	Citations
1	Identification of Tim4 as a phosphatidylserine receptor. Nature, 2007, 450, 435-439.	13.7	985
2	Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. Journal of Cellular Physiology, 1989, 140, 323-334.	2.0	786
3	Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene, 2000, 19, 624-631.	2.6	505
4	Identification and Characterization of a Constitutively Active STAT5 Mutant That Promotes Cell Proliferation. Molecular and Cellular Biology, 1998, 18, 3871-3879.	1.1	392
5	Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Experimental Hematology, 2003, 31, 1007-14.	0.2	346
6	Induction of human cardiomyocyte-like cells from fibroblasts by defined factors. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 12667-12672.	3.3	296
7	Phosphorylation by Aurora B Converts MgcRacGAP to a RhoGAP during Cytokinesis. Developmental Cell, 2003, 4, 549-560.	3.1	272
8	Identity of the elusive IgM Fc receptor (FcÎ¼R) in humans. Journal of Experimental Medicine, 2009, 206, 2779-2793.	4.2	205
9	FANTOM5 CAGE profiles of human and mouse samples. Scientific Data, 2017, 4, 170112.	2.4	195
10	MgcRacGAP Is Involved in Cytokinesis through Associating with Mitotic Spindle and Midbody. Journal of Biological Chemistry, 2001, 276, 5821-5828.	1.6	162
11	AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood, 2008, 111, 4297-4308.	0.6	146
12	Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation. Nature Communications, 2014, 5, 4177.	5.8	143
13	Myelodysplastic syndromes are induced by histone methylationÃ¢â‚¬â€œaltering ASXL1 mutations. Journal of Clinical Investigation, 2013, 123, 4627-4640.	3.9	140
14	A novel cell-cycle-indicator, mVenus-p27Kâ^', identifies quiescent cells and visualizes G0â€“G1 transition. Scientific Reports, 2014, 4, 4012.	1.6	134
15	Receptors for polytropic and xenotropic mouse leukaemia viruses encoded by a single gene at Rmc1. Nature Genetics, 1999, 21, 216-219.	9.4	125
16	Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation. Journal of Experimental Medicine, 2018, 215, 1729-1747.	4.2	113
17	Genetic regulation of the RUNX transcription factor family has antitumor effects. Journal of Clinical Investigation, 2017, 127, 2815-2828.	3.9	103
18	Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis. Journal of Clinical Investigation, 2005, 115, 919-929.	3.9	100

#	Article	IF	Citations
19	NFAM1, an immunoreceptor tyrosine-based activation motif-bearing molecule that regulates B cell development and signaling. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 8126-8131.	3.3	93
20	The Receptor LMIR3 Negatively Regulates Mast Cell Activation and Allergic Responses by Binding to Extracellular Ceramide. Immunity, 2012, 37, 827-839.	6.6	93
21	A signal sequence trap based on a constitutively active cytokine receptor. Nature Biotechnology, 1999, 17, 487-490.	9.4	89
22	Rac1 and a GTPase-activating protein, MgcRacGAP, are required for nuclear translocation of STAT transcription factors. Journal of Cell Biology, 2006, 175, 937-946.	2.3	89
23	Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis. Nature Communications, 2018, 9, 2733.	5.8	88
24	The role of ASXL1 in hematopoiesis and myeloid malignancies. Cellular and Molecular Life Sciences, 2019, 76, 2511-2523.	2.4	82
25	TIM1 is an endogenous ligand for LMIR5/CD300b: LMIR5 deficiency ameliorates mouse kidney ischemia/reperfusion injury. Journal of Experimental Medicine, 2010, 207, 1501-1511.	4.2	77
26	Role of exosomes as a proinflammatory mediator in the development of EBV-associated lymphoma. Blood, 2018, 131, 2552-2567.	0.6	76
27	A Rac GTPase-Activating Protein, MgcRacGAP, Is a Nuclear Localizing Signal-Containing Nuclear Chaperone in the Activation of STAT Transcription Factors. Molecular and Cellular Biology, 2009, 29, 1796-1813.	1.1	70
28	Expression Levels of Histone Deacetylases Determine the Cell Fate of Hematopoietic Progenitors. Journal of Biological Chemistry, 2009, 284, 30673-30683.	1.6	68
29	Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia. Blood, 2010, 115, 2872-2881.	0.6	67
30	Cell-surface MHC density profiling reveals instability of autoimmunity-associated HLA. Journal of Clinical Investigation, 2015, 125, 275-291.	3.9	62
31	Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis. Journal of Clinical Investigation, 2005, 115, 919-929.	3.9	62
32	Identification and characterization of a new pair of immunoglobulin-like receptors LMIR1 and 2 derived from murine bone marrow-derived mast cells. Biochemical and Biophysical Research Communications, 2003, 307, 719-729.	1.0	61
33	Arginine methylation controls the strength of Î³c-family cytokine signaling in T cell maintenance. Nature Immunology, 2018, 19, 1265-1276.	7.0	61
34	Disruption of Sept6, a Fusion Partner Gene of MLL, Does Not Affect Ontogeny, Leukemogenesis Induced by MLL-SEPT6, or Phenotype Induced by the Loss of Sept4. Molecular and Cellular Biology, 2005, 25, 10965-10978.	1.1	60
35	Two types of C/EBPÎ± mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models. Blood, 2011, 117, 221-233.	0.6	60
36	MgcRacGAP is involved in the control of growth and differentiation of hematopoietic cells. Blood, 2000, 96, 2116-2124.	0.6	54

#	Article	IF	Citations
37	Selective Cytotoxic Mechanism of GTP-14564, a Novel Tyrosine Kinase Inhibitor in Leukemia Cells Expressing a Constitutively Active Fms-like Tyrosine Kinase 3 (FLT3). Journal of Biological Chemistry, 2003, 278, 32892-32898.	1.6	54
38	An Activating and Inhibitory Signal from an Inhibitory Receptor LMIR3/CLM-1: LMIR3 Augments Lipopolysaccharide Response through Association with FcRÎ³ in Mast Cells. Journal of Immunology, 2009, 183, 925-936.	0.4	54
39	Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway. Nature Communications, 2021, 12, 1826.	5.8	54
40	A Novel Low-Density Lipoprotein Receptor-Related Protein Mediating Cellular Uptake of Apolipoprotein E-Enriched Î²-VLDL in Vitroâ€,â€¡. Biochemistry, 2000, 39, 15817-15825.	1.2	53
41	STAT5 Induces Macrophage Differentiation of M1 Leukemia Cells Through Activation of IL-6 Production Mediated by NF-ÎºB p65. Journal of Immunology, 2001, 167, 3652-3660.	0.4	53
42	Integrin Î±IIbÎ²3Induces the Adhesion and Activation of Mast Cells through Interaction with Fibrinogen. Journal of Immunology, 2006, 176, 52-60.	0.4	52
43	Functional Analysis of Activating Receptor LMIR4 as a Counterpart of Inhibitory Receptor LMIR3. Journal of Biological Chemistry, 2007, 282, 17997-18008.	1.6	52
44	Ceramide-CD300f binding suppresses experimental colitis by inhibiting ATP-mediated mast cell activation. Gut, 2016, 65, 777-787.	6.1	52
45	Truncation mutants of ASXL1 observed in myeloid malignancies areÂexpressed at detectable protein levels. Experimental Hematology, 2016, 44, 172-176.e1.	0.2	50
46	A novel ASXL1â€“OGT axis plays roles in H3K4 methylation and tumor suppression in myeloid malignancies. Leukemia, 2018, 32, 1327-1337.	3.3	50
47	Biological implications of somatic DDX41 p.R525H mutation in acute myeloid leukemia. Experimental Hematology, 2016, 44, 745-754.e4.	0.2	49
48	Sphingomyelin and ceramide are physiological ligands for human LMIR3/CD300f, inhibiting FcÎµRI-mediated mast cell activation. Journal of Allergy and Clinical Immunology, 2014, 133, 270-273.e7.	1.5	47
49	Exit from germinal center to become quiescent memory B cells depends on metabolic reprograming and provision of a survival signal. Journal of Experimental Medicine, 2021, 218, .	4.2	47
50	Molecular cloning of a novel type 1 cytokine receptor similar to the common gamma chain. Blood, 2000, 95, 2204-2210.	0.6	45
51	Analysis of mouse LMIR5/CLM-7 as an activating receptor: differential regulation of LMIR5/CLM-7 in mouse versus human cells. Blood, 2008, 111, 688-698.	0.6	44
52	Epigenetics in normal and malignant hematopoiesis: An overview and update 2017. Cancer Science, 2017, 108, 553-562.	1.7	44
53	Rab13 Small G Protein and Junctional Rab13-binding Protein (JRAB) Orchestrate Actin Cytoskeletal Organization during Epithelial Junctional Development. Journal of Biological Chemistry, 2012, 287, 42455-42468.	1.6	40
54	Clonal hematopoiesis and associated diseases: A review of recent findings. Cancer Science, 2021, 112, 3962-3971.	1.7	40

#	Article	IF	Citations
55	A GTPase-activating protein binds STAT3 and is required for IL-6â€“induced STAT3 activation and for differentiation of a leukemic cell line. Blood, 2004, 104, 3550-3557.	0.6	39
56	Roundabout 4 Is Expressed on Hematopoietic Stem Cells and Potentially Involved in the Niche-Mediated Regulation of the Side Population Phenotype. Stem Cells, 2009, 27, 183-190.	1.4	38
57	A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumors. Cell Death and Disease, 2019, 10, 529.	2.7	37
58	Recurrent RARB Translocations in Acute Promyelocytic Leukemia Lacking RARA Translocation. Cancer Research, 2018, 78, 4452-4458.	0.4	37
59	Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia. Nature Communications, 2019, 10, 4869.	5.8	36
60	Development of a Novel Selective Amplifier Gene for Controllable Expansion of Transduced Hematopoietic Cells. Blood, 1997, 90, 3884-3892.	0.6	35
61	Internalization of radioiodinated erythropoietin and the ligand-induced modulation of its receptor in murine erythroleukemia cells. International Journal of Cell Cloning, 1987, 5, 209-219.	1.6	31
62	Human CD300C Delivers an Fc Receptor-Î³-dependent Activating Signal in Mast Cells and Monocytes and Differs from CD300A in Ligand Recognition. Journal of Biological Chemistry, 2013, 288, 7662-7675.	1.6	31
63	Abnormal behaviours relevant to neurodevelopmental disorders in Kirrel3-knockout mice. Scientific Reports, 2018, 8, 1408.	1.6	31
64	PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma. Leukemia, 2020, 34, 2405-2417.	3.3	31
65	RUNX1/AML1 mutant collaborates with BMI1 overexpression in the development of human and murine myelodysplastic syndromes. Blood, 2013, 121, 3434-3446.	0.6	30
66	ASXL1 and SETBP1 mutations promote leukaemogenesis by repressing TGFÎ² pathway genes through histone deacetylation. Scientific Reports, 2018, 8, 15873.	1.6	30
67	ASXL1 mutation in clonal hematopoiesis. Experimental Hematology, 2020, 83, 74-84.	0.2	30
68	Transforming growth factorâ€Î²â€stimulated cloneâ€22 is a negativeâ€feedback regulator of Rasâ€Š/â€ŠRaf signaling: Implications for tumorigenesis. Cancer Science, 2012, 103, 26-33.	1.7	29
69	Ceramide-CD300f Binding Inhibits Lipopolysaccharide-induced Skin Inflammation. Journal of Biological Chemistry, 2017, 292, 2924-2932.	1.6	29
70	Discrimination of Dormant and Active Hematopoietic Stem Cells by G0 Marker Reveals Dormancy Regulation by Cytoplasmic Calcium. Cell Reports, 2019, 29, 4144-4158.e7.	2.9	27
71	A Soluble Form of LMIR5/CD300b Amplifies Lipopolysaccharide-Induced Lethal Inflammation in Sepsis. Journal of Immunology, 2012, 189, 1773-1779.	0.4	24
72	Cytokine Receptors: Structures and Signal Transduction. International Reviews of Immunology, 1998, 16, 617-634.	1.5	23

#	Article	IF	Citations
73	Disrupting ceramide-CD300f interaction prevents septic peritonitis by stimulating neutrophil recruitment. Scientific Reports, 2017, 7, 4298.	1.6	23
74	v-Src suppresses SHPS-1 expression via the Ras-MAP kinase pathway to promote the oncogenic growth of cells. Oncogene, 2000, 19, 1710-1718.	2.6	22
75	Advances in Cytokinesis Research. Role of MgcRacGAP/Cyk4 as a Regulator of the Small GTPase Rho Family in Cytokinesis and Cell Differentiation.. Cell Structure and Function, 2001, 26, 645-651.	0.5	21
76	In vitro validation of bioluminescent monitoring of disease progression and therapeutic response in leukaemia model animals. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 557-565.	3.3	21
77	Spine Formation Pattern of Adult-Born Neurons Is Differentially Modulated by the Induction Timing and Location of Hippocampal Plasticity. PLoS ONE, 2012, 7, e45270.	1.1	20
78	The molecular basis of myeloid malignancies. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2014, 90, 389-404.	1.6	20
79	The ubiquitin ligase STUB1 regulates stability and activity of RUNX1 and RUNX1â€“RUNX1T1. Journal of Biological Chemistry, 2017, 292, 12528-12541.	1.6	20
80	Activation of CpG-Rich Promoters Mediated by MLL Drives MOZ-Rearranged Leukemia. Cell Reports, 2020, 32, 108200.	2.9	20
81	The shortest isoform of C/EBPÎ², liver inhibitory protein (LIP), collaborates with Evi1 to induce AML in a mouse BMT model. Blood, 2013, 121, 4142-4155.	0.6	19
82	Overexpression of RUNX1 short isoform has an important role in the development of myelodysplastic/myeloproliferative neoplasms. Blood Advances, 2017, 1, 1382-1386.	2.5	19
83	Possible involvement of RasGRP4 in leukemogenesis. International Journal of Hematology, 2009, 89, 470-481.	0.7	18
84	Characterization of Leukocyte Mono-immunoglobulin-like Receptor 7 (LMIR7)/CLM-3 as an Activating Receptor. Journal of Biological Chemistry, 2010, 285, 35274-35283.	1.6	18
85	Hes1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells. Blood, 2014, 123, 3932-3942.	0.6	18
86	Imaging dynamic mTORC1 pathway activity in vivo reveals marked shifts that support time-specific inhibitor therapy in AML. Nature Communications, 2021, 12, 245.	5.8	18
87	Structural and functional analyses of glycosylation on the distinct molecules of human GM-CSF receptors. FEBS Journal, 1991, 198, 659-666.	0.2	17
88	APCCDH1 Targets MgcRacGAP for Destruction in the Late M Phase. PLoS ONE, 2013, 8, e63001.	1.1	17
89	Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms. International Journal of Hematology, 2019, 110, 179-186.	0.7	17
90	CHIPâ€associated mutant ASXL1 in blood cells promotes solid tumor progression. Cancer Science, 2022, 113, 1182-1194.	1.7	17

#	Article	IF	Citations
91	NUP98-HBO1â€“fusion generates phenotypically and genetically relevant chronic myelomonocytic leukemia pathogenesis. Blood Advances, 2019, 3, 1047-1060.	2.5	16
92	A histone modifier, ASXL1, interacts with NONO and is involved in paraspeckle formation in hematopoietic cells. Cell Reports, 2021, 36, 109576.	2.9	15
93	The CD300e molecule in mice is an immune-activating receptor. Journal of Biological Chemistry, 2018, 293, 3793-3805.	1.6	14
94	ASXL1 mutations gain a function. Blood, 2018, 131, 274-275.	0.6	13
95	Efficient retroviral transduction of human B-lymphoid and myeloid progenitors: marked inhibition of their growth by the Pax5 transgene. International Journal of Hematology, 2008, 87, 351-362.	0.7	12
96	Evidence That Integrin Î±IIbÎ²3-dependent Interaction of Mast Cells with Fibrinogen Exacerbates Chronic Inflammation. Journal of Biological Chemistry, 2009, 284, 31463-31472.	1.6	12
97	Molecular bases of myelodysplastic syndromes: Lessons from animal models. Journal of Cellular Physiology, 2009, 219, 529-534.	2.0	12
98	The phytosphingosine-CD300b interaction promotes zymosan-induced, nitric oxideâ€“dependent neutrophil recruitment. Science Signaling, 2019, 12, .	1.6	12
99	Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors. Nature Communications, 2022, 13, 271.	5.8	12
100	Induction of Synaptosomal-Associated Protein-23 kD (SNAP-23) by Various Cytokines. Blood, 1998, 92, 129-135.	0.6	11
101	HHEX promotes myeloid transformation in cooperation with mutant ASXL1. Blood, 2020, 136, 1670-1684.	0.6	11
102	Identification of RHOXF2 (PEPP2) as a cancer-promoting gene by expression cloning. International Journal of Oncology, 2012, 40, 93-8.	1.4	10
103	Opposing effects of acute versus chronic inhibition of p53 on decitabineâ€™s efficacy in myeloid neoplasms. Scientific Reports, 2019, 9, 8171.	1.6	10
104	MDS cells impair osteolineage differentiation of MSCs via extracellular vesicles to suppress normal hematopoiesis. Cell Reports, 2022, 39, 110805.	2.9	10
105	A C-terminal mutant of CCAAT-enhancer-binding protein Î± (C/EBPÎ±-Cm) downregulates Csf1r, a potent accelerator in the progression of acute myeloid leukemia with C/EBPÎ±-Cm. Experimental Hematology, 2015, 43, 300-308.e1.	0.2	9
106	Hes1 upregulation contributes to the development of FIP1L1-PDGRAâ€“positive leukemia in blast crisis. Experimental Hematology, 2014, 42, 369-379.e3.	0.2	8
107	Overexpression of Lhx2 suppresses proliferation of human T cell acute lymphoblastic leukemia-derived cells, partly by reducing LMO2 protein levels. Biochemical and Biophysical Research Communications, 2018, 495, 2310-2316.	1.0	8
108	Role of the Ceramide-CD300f Interaction in Gram-Negative Bacterial Skin Infections. Journal of Investigative Dermatology, 2018, 138, 1221-1224.	0.3	8

#	Article	IF	Citations
109	Mouse LIMR3/CD300f is a negative regulator of the antimicrobial activity of neutrophils. Scientific Reports, 2018, 8, 17406.	1.6	8
110	Upregulation of CD200R1 in lineage-negative leukemic cells is characteristic of AML1-ETO-positive leukemia in mice. International Journal of Hematology, 2012, 96, 638-648.	0.7	7
111	MicroRNA-125b-1 accelerates a C-terminal mutant of C/EBPÎ± (C/EBPÎ±-Cm)-induced myeloid leukemia. International Journal of Hematology, 2012, 96, 334-341.	0.7	7
112	Constitutive phosphorylation of a Rac GAP MgcRacGAP is implicated in vâ€Srcâ€induced transformation of NIH3T3 cells. Cancer Science, 2009, 100, 1675-1679.	1.7	6
113	Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models. International Journal of Hematology, 2012, 95, 167-175.	0.7	6
114	ASXL1 as a critical regulator of epigenetic marks and therapeutic potential of mutated cells. Oncotarget, 2018, 9, 35203-35204.	0.8	6
115	The ubiquitin ligase RNF38 promotes RUNX1 ubiquitination and enhances RUNX1-mediated suppression of erythroid transcription program. Biochemical and Biophysical Research Communications, 2018, 505, 905-909.	1.0	6
116	Leukocyte mono-immunoglobulin-like receptor 8 (LMIR8)/CLM-6 is an FcRÎ³-coupled receptor selectively expressed in mouse tissue plasmacytoid dendritic cells. Scientific Reports, 2018, 8, 8259.	1.6	6
117	Tyk2 Is Dispensable for Induction of Myeloproliferative Disease by Mutant FLT3. International Journal of Hematology, 2006, 84, 54-59.	0.7	5
118	Profiles of anemia in adolescent students with sports club membership in an outpatient clinic setting: a retrospective study. PeerJ, 2022, 10, e13004.	0.9	5
119	Novel working hypothesis for pathogenesis of hematological malignancies: combination of mutations-induced cellular phenotypes determines the disease (cMIP-DD). Journal of Biochemistry, 2016, 159, 17-25.	0.9	4
120	Enforced expression of MIR142, a target of chromosome translocation in human B-cell tumors, results in B-cell depletion. International Journal of Hematology, 2018, 107, 345-354.	0.7	4
121	Immune Suppressor Factor Confers Enhanced Supporting Activity for Hematopoietic Stem Cells in Bone Marrow Stroma.. Blood, 2004, 104, 509-509.	0.6	4
122	TROY, a Novel Member of the Tumor Necrosis Factor Receptor Superfamily in the Central Nervous System. Annals of the New York Academy of Sciences, 2006, 1088, A1-A10.	1.8	3
123	HDACI-induced thrombocytopenia is caused by its unexpected target. Experimental Hematology, 2012, 40, 695-697.	0.2	3
124	Efficacy of tyrosine kinase inhibitors on a mouse chronic myeloid leukemia model and chronic myeloid leukemia stem cells. Experimental Hematology, 2020, 90, 46-51.e2.	0.2	3
125	Comprehensive expression pattern of kin of irregular chiasm-like 3 in the adult mouse brain. Biochemical and Biophysical Research Communications, 2021, 563, 66-72.	1.0	3
126	Inhibition of Impdh As an Effective Treatment for MLL-Fusion Leukemia. Blood, 2016, 128, 750-750.	0.6	3

#	Article	IF	Citations
127	Leaving IJH: joining to fly. International Journal of Hematology, 2017, 105, 1-2.	0.7	2
128	Protease-Activated Receptor 1 (PAR-1) Inhibits Proliferation but Enhances Leukemia Stem Cell Activity in Acute Myeloid Leukemia. Blood, 2016, 128, 2730-2730.	0.6	2
129	The Ubiquitin Ligase DTX2 Promotes Nuclear Export of RUNX1 and Inhibits RUNX1-Dependent Leukemogenesis. Blood, 2019, 134, 1252-1252.	0.6	1
130	A method for gene transfer, single isolation and in vitro assay for neural stem cells. Ensho Saisei, 2005, 25, 50-54.	0.2	1
131	Guest editorial: Genetic and epigenetic alterations in hematopoietic malignancies. International Journal of Hematology, 2013, 97, 163-164.	0.7	0
132	Epigenetic abnormalities and therapies for hematological malignancies. International Journal of Hematology, 2019, 110, 147-149.	0.7	0
133	Guest Editorial. Experimental Hematology, 2020, 83, 1.	0.2	0
134	The Hsp90 Inhibitor 17-AAG and FLT3 Kinase Inhibitor GTP14564 Synergistically Inhibit MLL Fusion Gene Leukemias with FLT3 Mutations.. Blood, 2004, 104, 1167-1167.	0.6	0
135	A Novel Method for Efficient Production of Multipotential Hematopoietic Progenitors from Human Embryonic Stem Cells by Co-Culture with Murine Fetal Liver-Derived Stromal Cells.. Blood, 2005, 106, 4214-4214.	0.6	0
136	Constitutive Expression of Pax5 in Cord Blood Progenitor Cells Rather Inhibits B Lymphopoiesis as Well as Myelopoiesis through the Exon 9-Dependent and Independent Mechanism.. Blood, 2005, 106, 2718-2718.	0.6	0
137	Robo4/Magic Roundabout Is a Novel Surface Marker for Murine and Human Hematopoietic Stem Cells.. Blood, 2006, 108, 682-682.	0.6	0
138	Junctional Adhesion Molecule-A (JAM-A/JAM-1/F11R) Marks Long-Term Repopulating Hematopoietic Stem Cells.. Blood, 2007, 110, 1270-1270.	0.6	0
139	Nov/CCN3 Enhances Long-Term Repopulating Activity of Mouse Hematopoietic Stem Cells Via Intergin Î²3 Signaling Collaborating with Thrombopoietin. Blood, 2011, 118, 862-862.	0.6	0
140	RUNX1/AML1 Mutants Collaborate with BMI1 in the Development of Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukemia (AML) in a Mouse BMT Model.. Blood, 2012, 120, 2820-2820.	0.6	0
141	SETBP1 Mutations Drive Leukemic Transformation in ASXL1-Mutated MDS. Blood, 2014, 124, 525-525.	0.6	0
142	A Patient-Derived EZH2 Mutant Induces MDS-like Diseases with Derepressed ABCG2 Expression in Mice. Blood, 2015, 126, 4116-4116.	0.6	0
143	A p53-MDM2 Interaction Inhibitor, DS-5272, Inhibits the Development of MLL-Fusion Leukemia with the Assistance of Tumor Immunity. Blood, 2017, 130, 796-796.	0.6	0
144	Leukemogenic Functions of Mutant ASXL1 Are Regulated By CDK-Mediated Phosphorylation. Blood, 2019, 134, 731-731.	0.6	0

#	Article	IF	Citations
145	Mutant ASXL1 Disrupts Paraspeckle Formation through Aberrant Interaction with Nono in Hematopoietic Cells. Blood, 2019, 134, 2514-2514.	0.6	0
146	Impaired Osteoblastic Differentiation of MSCs Suppresses Normal Hematopoiesis in MDS. Blood, 2020, 136, 17-18.	0.6	0
147	UBC9 inhibits myeloid differentiation in collaboration with AML1-MTG8. International Journal of Hematology, 2022, , 1.	0.7	0
148	CRISPR/Cas9-mediated base-editing enables a chain reaction through sequential repair of sgRNA scaffold mutations. Scientific Reports, 2021, 11, 23889.	1.6	0